Research programme: BRCC3 - Insys TherapeuticsAlternative Names: BRCC3 research programme - Insys Therapeutics
Latest Information Update: 19 Oct 2016
At a glance
- Originator NeoPharm Inc
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 08 May 2007 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
- 12 Nov 2001 New profile
- 12 Nov 2001 Preclinical development for Breast cancer in USA (Unknown route)